pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,498
stories
Sep 1, 26
STAT+: 5 burning questions on Trump’s latest deals with drugmakers
stat
Sep 1, 26
Roche taps Simcere for trispecific T cell engager pact with $75M upfront
endpoints
Sep 1, 26
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality
biospace
Sep 1, 26
STAT+: Novartis gets multiple sclerosis win with BTK inhibitor
stat
Sep 1, 26
STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
stat
Sep 1, 26
ArsenalBio sacrifices ‘majority’ of staff in pivot to in vivo CAR T
biospace
Sep 1, 26
STAT+: Will House delay Trump plan to politicize NIH grants?
stat
Sep 1, 26
9 midsize drugmakers climb aboard Trump’s MFN train
biospace
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Sep 1, 26
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
Sep 1, 26
Novocure hit by cyberattack exposing patient data
fiercebiotech
Sep 1, 26
Opinion: The Trump administration is burying science and health care in paperwork
stat
Aug 31, 26
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
biopharma dive
Aug 31, 26
New guidelines on migraine prevention reflect increasing options for patients
stat
Aug 31, 26
STAT+: Trump strikes nine more deals with drugmakers to lower prices
stat
Aug 31, 26
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
fiercebiotech
Aug 31, 26
FDA OKs Takeda, Protagonist drug for rare blood cancer
biopharma dive
Aug 31, 26
STAT+: Can buying a drug patent application be seen as a bid to prolong a monopoly?
stat
Aug 31, 26
STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more
stat
Aug 31, 26
STAT+: Can a pregnancy hormone steer a cardiovascular treatment?
stat
Aug 31, 26
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 31, 26
STAT+: After a rough stretch, mRNA gets a boost — at least for now
stat
Aug 31, 26
Natera teams with Angiex on cancer drug trial monitoring
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 31, 26
Recon: FDA approves Protagonist and Takeda’s drug for rare blood cancer; Lilly to buy Merida for up to $2.88B
raps
← prev
page 16 of 50
next →
